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Preparation of a superantigen-adsorbing device and its 
superantigen removal effkacies in vitro and in vivo 
Keishi Miwa,(l) Mayumi Fukuyama,(i) Nobuo Ida,(‘) Hideo Igarashic2) and Takehiko Uchiyamac3) 
Objective: A new superantigen-adsorbing device (SAAD) was developed, and its characteristics and efficacy in 
septic animals were evaluated. 
Methods: The SAAD was prepared by stepwise chemical modification of a polystyrene-based composite fiber rein- 
forced with polypropylene. Adsorption affinities for several factors and the biological effect of superantigen (SAg) 
removal were measured in vitro. Also, superantigen-infused rabbits were treated with SAAD, and the efficacy was 
evaluated in vivo. 
Results: When the SAAD was evaluated for its ability to adsorb SAg in human plasma (1 ng/mL each), the adsorp- 
tion rates were 74%, 76% and 85% for staphylococcal enterotoxins A, B and C, respectively, and 80% and 72% for 
toxic shock syndrome toxin-l (TSST-1) and streptococcal pyrogenic exotoxin A, respectively. In addition, the SAAD 
showed some affinity towards other molecules, such as streptococcal pyrogenic exotoxin B, B2-microglobulin, and 
vancomycin. Residual activities in whole blood samples containing TSST-1 (1 ng/mL) after incubation with the 
SAAD were 125 pg/mL for tumor necrosis factor alpha (TNF-ar) production, and 359 pg/mL for interleukin-8 (IL- 
8) production (the initial activities: 194 pg/mL for TNF-(-w production, and 1029 pg/mL for IL-8 production). When 
TSST-l/lipopolysaccharide (LPS)-infused rabbits were subjected to extracorporeal blood purification with a SAAD 
column, 50% of the animals survived for a 14-day period after the infusion. In contrast, all control animals died within 
3 days after the infusion. 
Conclusion: These results indicate that the SAg-adsorbing device may be useful in treating SAg-related diseases. 
Int J Infect Dis 2003; 7: 21-28 
INTRODUCTION 
Gram-positive sepsis is one of the serious problems 
seen in severe bacterial infections.1,2 Several bacterial 
products, such as staphylococcal enterotoxins A-E 
(SEA-SEE), toxic shock syndrome toxin-l (TSST-l), 
streptococcal pyrogenic exotoxins A and C (SPEA and 
SPEC), streptococcal mitogenic exotoxins, and Yersinia- 
derived mitogen,” have recently been shown to have 
superantigenic activities and are now generally recog- 
nized as superantigens (SAgs). 
There is accumulating evidence that SAgs are 
pathogenic substances causing systemic inflammation, 
sepsis, septic shock, and subsequent multiple organ fail- 
ure. In fact, SAgs have been shown to be present in the 
peripheral blood of patients with toxic shock syndrome 
(TSS) and streptococcal toxic shock syndrome (STSS).4J 
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Our recent studies have shown that SAgs bind to the 
major histocompatibility complex (MHC) class II; this 
event is linked to activation of T cells and induction of 
pro-inflammatory cytokine production.h Furthermore, 
similar to the case reported with a SAg-related VP, 
specific T-cell expansion was observed in patients 
with TSS,’ neonatal TSS-like exanthematous disease 
(NTED),s and methicillin-resistant Staphylococcus 
aureus (MRSA)-associated glomerulonephritis.9 
Considering that SAgs are present in circulating 
blood and play a major role in the pathogenesis of sepsis 
during the course of bacterial infections, one of the most 
direct and promising methods to prevent the develop- 
ment of sepsis would be removal of systemically 
circulating SAgs from the body fluid by extracorporeal 
circulation. Although various polymers, including ion- 
exchange resins and polymer-coated activated char- 
coal, have been examined,tO-I2 none of these polymers 
exhibited suitable characteristics, especially in terms of 
SAg adsorption specificity and bloodflow resistance, for 
practical use as adsorbents in clinical settings. 
In the present study, we have developed a new SAg- 
adsorbing device (SAAD) that can be used in extra- 
corporeal circulation in clinical settings. The device was 
prepared by chemical modification of a polystyrene- 
based composite fiber reinforced with polypropylene. 
This paper describes the preparation of the device and 
its effectiveness in adsorbing SAgs in vitro and in vivo. 
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MATERIALS AND METHODS 
Chemicals, biological preparations, and animals 
The purified SAgs (SEA, SEB, SEC,TSST-1, and SPEA) 
and SPEB were purchased from Toxin Technology 
(Sarasota, FL, USA); staphylococcal protein A (Protein 
A) was obtained from EY Laboratory (San Mateo, CA, 
USA); anti-ProteinA chicken polyclonal antibody was 
obtained from Biogenesis (Poole, UK); Pseudomonas 
exotoxin A (ExA) and anti-ExA antibody were obtained 
from LIST Biology Laboratories (Campbell, CA, USA); 
lipoteichoic acid (LTA) (derived from S. aureus) was 
obtained from Sigma (St Louis, IL, USA); endotoxin 
(lipopolysaccharide (LPS), peptidoglycan (derived from 
Micrococcus luteus)(PepG) and reagent kits for LPS- 
specific limulus assay and silkworm larva plasma (SLP) 
reagent assay were obtained from Wako Pure Chemicals 
(Tokyo, Japan); the purified recombinant cytokines, 
human interleukin (IL)-6, human IL-S, human macro- 
phage chemoattractant protein 1 (MCP-1) and human 
tumor necrosis factor alpha (TNF-(-w), were obtained 
from Genzyme Techne (Minneapolis, MN, USA); and 
human plasminogen activator inhibitors of the active 
form (PAI-la) and latent form (PAI-11) were obtained 
from Molecular Innovation (Southfield, MI, USA). 
Polyclonal antibodies against SPEB, LTA, PAI-la, 
and PAI- were prepared by immunization of rabbits 
with the respective purified antigens. 
Vancomycin (VCM) and cefaclor (CCL) were 
obtained from Shionogi Pharmaceuticals (Osaka, 
Japan), arbekacin (ABK) and penicillin G (PCG) were 
obtained from Meiji Seika (Tokyo, Japan), clindamycin 
(CLDM) was obtained from Pharmacia and Upjohn 
(Tokyo, Japan), and miconazole (MCZ) was obtained 
from Mochida Pharmaceuticals (Tokyo, Japan). 
With the approval of the Institutional Review Board 
of Toray Pioneering Research Laboratory, blood samples 
were collected from healthy volunteers. Heparin was 
added to each blood sample to give a concentration of 
5 unit/ml immediately after collection. Heparinized 
blood was taken in aliquots of 50 mL and centrifuged at 
2000g (3000 rev/min) to separate plasma samples. 
Male New Zealand white rabbits, 13-15 weeks old, 
weighing 2.5-3.0 kg, were obtained from a local supplier 
(Shimizu Laboratory Supplies, Kyoto, Japan). 
Preparation of superantigen adsorbent 
A polystyrene-based composite fiber reinforced with 
polypropylene was prepared by a method described 
elsewhere.” 
Chemical modification of the composite fiber was 
carried out by an adaptation of a previously described 
method.14 In the first step of the modification, composite 
fiber (100 g) was treated with N-methylol-a-chloro- 
acetamide (182 g) in a mixture of sulfuric acid (1300 g) 
and nitrobenzene (1300 g) at 15°C for 2 h in the presence 
of paraformaldehyde (2.6 g).The treated fiber was washed 
once with nitrobenzene and five times with methanol. 
The fiber was dried at room temperature. In the second 
step, the fiber was treated with tetraethylenepentamine 
(47 g, Katayama Chemical, Osaka, Japan) and triethyl- 
amine (77 g, Katayama Chemical) in dimethylformamide 
(DMF, 3000 mL) for 3 h with mechanical stirring at 
30°C. The resulting fiber was thoroughly washed with 
DMF. In the third step, the fiber was reacted with 4- 
chlorophenylisocyanate (72 g, Aldrich, Milwaukee, WI, 
USA) in DMF (3000 mL) at 30°C for 1 h with stirring. 
The reacted fiber was thoroughly washed with DMF and 
then with pyrogen-free distilled water. The urea-bond 
fiber thus obtained was sterilized in pyrogen-free saline 
by irradiation with gamma rays (2.5 Mrad), and then 
kept at 4°C until use. 
Quantification of the functional group 
The number of functional groups (4-chlorophenylurea 
groups) bound to the fiber was quantitated by spectro- 
photometric determination of 4-chloroaniline released 
from the fiber on hydrolysis. Hydrolysis of the SAAD 
(0.25 g) was carried out in 6 M hydrochloric acid (4 mL) 
for 20 h at 110°C. For quantitation of the released 4- 
chloroaniline, 1 mL of the supernatant of the reaction 
mixture was mixed with 0.5 M hydrochloric acid (1 mL). 
To the mixture, sodium nitrite (0.04 mg), ammonium 
sulfamate solution (3 mg/mL, 1 mL) and N-l-naphthyl- 
ethylenediamine dihydrochloride solution (0.7 mg/mL, 
1 mL) were added, in that order. The reaction mixture 
was allowed to stand at room temperature for 30 min, 
and then read spectrophotometrically at 545 nm. 
Measurement of superantigens and other 
bacterial products 
SAgs were measured by the ELISA method previously 
reported.15 Briefly, samples were diluted two-fold with 
Tris-HCl buffer (pH 8.0) containing 0.25% bovine serum 
albumin (BSA), 0.05% Tween-20,10 kg/mL mouse IgG, 
and 10 ug/mL rabbit IgG. The diluted samples were 
placed in wells of an anti-SAg polyclonal antibody 
immobilized ELISA plate (Nunc, Roskilde, Denmark). 
The plate was incubated for 1 h at 25°C and each well 
was then treated with horseradish peroxidase (HRP)- 
labeled monoclonal antibody to the given SAg. The 
peroxidase activity was visualized by the reaction with 
3,3’,5,5’-tetramethylbenzidine (0.2 mg/mL) in 0.1 M 
citric acid, pH 3.5, in the presence of hydrogen peroxide 
(0.9%) at room temperature for 30 min. The reaction 
was terminated with 0.5 M sulfuric acid, and the reaction 
mixture was read spectrophotometrically at 450 nm. 
Standard solutions were prepared by serial dilution of 
the SAg original solution in phosphate-buffered saline 
(PBS) containing 0.25% BSA and 0.05% Tween-20. 
Each of the polyclonal antibodies was confirmed to be 
specific to the given SAg and to exhibit no significant 
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cross-reactivity with any of the other SAgs, fetal bovine 
serum, or healthy human plasma. 
The bacterial products SPEB, ProteinA, ExA and 
LTA were also quantified by ELISA in a manner similar 
to that described above for quantitation of SAgs, except 
that unlabeled polyclonal and HRP-labeled polyclonal 
antibodies against these bacterial products were used as 
the capture and detecting antibodies, respectively. 
Endotoxin (LPS) and PepG were measured by the LPS- 
specific limulus assay and SLP reagent assay, respect- 
ively, using the respective purified toxin preparations as 
the standards. 
Measurement of cytokines 
Concentrations of the cytokines IL-6, IL-S and MCP-1 
were measured by ELISA,i6-‘s using purified recom- 
binant cytokines as the standards. 
In vitro batch adsorption of superantigens 
in fetal calf serum 
In order to minimize the contribution of nonspecific 
adsorption, the SAAD (0.06 g) was pretreated with BSA 
(0.5 mg/mL) in PBS (pH 7.4, 2 mL) for 1 h at room 
temperature. The BSA-pretreated SAAD (0.06 g) was 
incubated with SEA, SEB, SEC, TSST-1 or SPEA 
(1 ng/mL) in fetal calf serum (FCS, 1 mL) at 37°C for 2 
h with gentle rotary mixing. The supernatant of the 
resulting incubation mixture was analyzed for the 
residual concentration of the superantigen by ELISA. 
In vitro adsorption of non-superantigenic bacterial 
products, cytokines and antimicrobials 
The rates of adsorption on the SAAD of various non- 
superantigenic bacterial products, cytokines and anti- 
biotics were examined in a similar manner to that 
described above for adsorption of SAgs. The initial con- 
centrations were: SPEB, 1 ng/mL; ProteinA, 10 ng/mL; 
ExA, 10 ng/mL; LPS, 1 ng/mL; LTA, 100 ng/mL; PepG, 
10 ng/mL; TNF-a, 10 ng/mL; IL-6, 10 ng/mL; IL-S, 
10 ng/mL; MCP-1, 10 ng/mL; PAI-la, 10 ng/mL; PAI-11, 
10 ng/mL; VCM, 50 kg/mL; ABK, 10 kg/mL; PCG, 
10 Fg/mL; CLDM, 20 pg/mL; CCL, 20 p,g/mL; MCZ, 
10 p,g/mL. The initial concentrations of the antimicro- 
bials were selected according to the maximum plasma 
concentrations in patients seen in clinical settings. 
In vitro adsorption of human plasma proteins 
Human plasma was incubated in the presence of the 
SAAD at 37°C for 2 h. After removal of the SAAD, the 
plasma was analyzed for the residual levels of total 
protein (TP), albumin (Alb), immunoglobulins G, A 
and M (IgG, IgA, IgM), high-density and low-density 
lipoprotein (HDL and LDL), complement factors 3, 4 
and 5 (C3, C4, CS), p 2 - microglobulin (p2MG), bilirubin 
(Bil) and myoglobin (Mgb) by the conventional methods. 
Biological effect of superantigen removal 
(cytokine induction assay) 
TSST-l-challenged plasma was prepared by the addition 
of TSST-1 to human plasma at a concentration of 
1 ng/mL. TSST-l-challenged plasma was incubated at 
37°C for 2 h in the presence of the SAAD (0.065 g/mL, 
2 cm2/mL). In a control experiment, TSST-l-challenged 
plasma was incubated in a similar manner, but in the 
absence of the SAAD. A portion of the incubated plasma 
was examined by ELISA for the TSST-1 concentration, 
and another portion of the plasma was examined for 
cytokine production-inducing activities. 
For determining the cytokine production-inducing 
activities, the plasma was added to an equal volume of 
2.5-fold-diluted human whole blood with RPMI-1169. 
The mixture was incubated at 37°C for 12 h, and centri- 
fuged at 2000g (3000 rev/min). The concentrations of 
TNF-a and IL-S in the resulting supernatant were deter- 
mined by ELISA. 
Animal experiments 
The protocol for the animal experiment was reviewed 
and approved by the Institutional Animal Care and Use 
Committee of Toray Pioneering Research Laboratories. 
In total, 16 rabbits were used: eight were treated 
with a column containing 6.6 g of SAAD fiber (SAAD 
column), and eight were treated with an empty column 
with the same priming volume (control column). Rabbits 
were anesthetized with sodium pentobarbital by intra- 
venous administration at 30 mg/kg. Anesthesia was 
maintained by giving an additional 15 mg/kg dose of 
sodium pentobarbital 2 h after the first injection. The 
animals were individually subjected to direct hemo- 
perfusion by pumping out blood from the right femoral 
artery through a cannulated tube, passing it into a 
SAAD or control column, and returning it into the right 
femoral vein of the rabbit. Using an electronically con- 
trolled infusion pump (TERUMO Corp.,Tokyo, Japan), 
saline containing heparin (100 unit/ml) was infused 
continuously at a flow rate of 3 ml/h to prevent coagula- 
tion. 
Animals were allowed to be relaxed during the 
initial 15-min period after the initiation of the extra- 
corporeal blood circulation. TSST-1 was then infused at 
a flow rate of 0.05 Fg/kg per hour for 1 h. After a l-h 
interval from the completion of TSST-1 infusion, LPS 
was infused from downstream of the hemoperfusion 
circulation at a flow rate of 0.27 pg/kg per hour for 1 h, 
to induce shock. Direct hemoperfusion at a flow rate 
of 10 mUmin was performed from 15 min before the 
infusion of TSST-1 until 3.5 h after this. After the com- 
pletion of hemoperfusion, all of the blood in the circuit 
was returned to the rabbit, the cannulated tubes were 
removed, and the incisions were closed under sterile 
conditions. The animals were then allowed to recover 
from anesthesia, and observed for 3 h after the com- 
pletion of hemoperfusion and daily thereafter for 14 
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days. Survival rates in a 14-day period after the treat- 
ment were evaluated. After 14 days, the animals were 
killed with a lethal dose of sodium pentobarbital. 
Blood samples were collected from the inlet and 
-(CHz-CH),- 
0 c WQ) 
outlet of the column in the hemoperfusion circuit. 
HzSOJNitrobenzene HO-CHZ-NH-CO-CHz-Cl 
P* 
Stage 1 
Plasma was separated from each blood sample for the 
N-methylol-cw-chloracetamide 
determination of TSST-1 concentrations by ELISA. -(CH2-CH),- 
Blood cell counts, blood gas and blood pH were also 
measured. Blood pressure was measured with a mano- 0 c (AMPSt) 
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artery. Dimethylformamide 
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/\\ 
The data regarding in vitro clearance of superantigens, U ‘I 
cytokine production and TSST-1 concentrations in 
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column were compared by paired t-test, and the survival -(CH2-CH),- 
rates were analyzed by the Kaplan-Meier method. 0 I > WADI I--\ 
RESULTS 
Preparation of superantigen-adsorbing device (SAAD) 
As shown in Figure 1, chemical modification of a 
polystyrene-based composite fiber reinforced with 
polypropylene was carried out in the following three 
steps: (1) cx-chloroacetoamidomethylation of the fiber 
on phenyl rings of the polystyrene component; (2) intro- 
duction of polyamine spacer molecules into the aceto- 
amidomethyl moieties by the reaction with tetra- 
ethylenepentamine; and (3) modification of the terminal 
amino groups of the attached spacer molecules with 4- 
chlorophenylisocyanate to form 4-chlorophenylurea 
groups. 
Under the conditions employed in the present study, 
0.8 mmol of 4-chlorophenylurea groups was introduced 
for each gram of the fiber. No significant changes were 
noted in the TSST-l-adsorbing abilities of the resulting 
fiber after gamma ray irradiation at 2.5 Mrad or 6 
months of storage at 4°C (data not shown). 
Adsorption characteristics of the SAAD 
The SAg-adsorbing ability of the SAAD was first 
examined in vitro by incubating the SAAD (0.065 g, 
total surface area 2 cmz) with various SAgs (1 ng/mL) in 
FCS (1 mL) at 37°C for 2 h. The adsorption of TSST-1 
occurred in a time-dependent manner, and reached a 
plateau at 2 h (data not shown). Thus, the adsorption 
rates determined in 2-h incubations were used as the 
index in the evaluation of selectivity of SAg adsorption 
by the SAAD. The resulting adsorption rates were 
sufficientlv hinh: 74%. 76% and 75 % for SEA, SEB and 
CH2NHCOCH2-(NHCH2CH&-NHCONH \ / Cl 
v 
Figure 1. Synthesis flowchart of the superantigen-adsorbing 
device (SAAD). Stage 1: conversion of polystyrene (PSt), 
a component of the composite fiber, to a-chloroaceto- 
amidomethylated polystyrene (AMPSt). Stage 2: introduction 
of polyamine spacers into AMPSt by the reaction with 
tetraethylenpentamine. Stage 3: formation of the functional 
groups, 4xhlorophenylurea groups, at the free terminal of the 
polyamine spacers attached to AMPSt. 
Similar levels of adsorption were observed in 
incubations with non-superantigenic bacterial products 
such as SPEB (85%) and LTA (75%) (Figure 2B). In 
general, however, the SAAD exhibited rather poor 
affinities for non-superantigenic bacterial products, as 
shown by the adsorption rates of 49%, lo%, 50% and 
5% for ProteinA, ExA, LPS and PepG, respectively 
(Figure 2B). 
Rather high adsorption rates were noted in incuba- 
tions with cytokines under similar conditions: the result- 
ing rates were 90% and 89% for IL-8 and MCP-1, 
respectively (Figure 2C). In addition, the SAAD showed 
some affinities for antibiotics; the adsorption rates were 
67%) 68%, 50% and 83% for PCG, CCL, MCZ and 
VCM, respectively (Figure 2D). 
When heparinized human plasma samples were 
incubated in the presence or absence of the SAAD 
(0.065 g/mL), relatively high adsorption was noted only 
for P2MG, Bil, and Mgb (84%, 75%, and 80%, respec- 
tively) (Figure 2E). In contrast, no significant adsorption 
was observed with TP, Alb, IgG, IgA, IgM, HDL, LDL, 
C3, C4, and C5 (less than 5%). 
Superantigen-removal efficacy of the SAAD 
SEC, resp&Lely, and 80% and 72% for TSST-1 and The SAg-removal efficacy of the SAAD was also 
SPEA, respectively (Figure 2A). examined by assessing the ability of TSST-1 to induce 
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Figure 2. Abilities of the superantigen-adsorbing device (SAAD) to adsorb superantigens and other related materials. (A) 
Superantigens at 1 ng/mL (SEA, staphylococcal enterotoxin A; SEE, staphylococcal enterotoxin B; SEC, staphylococcal enterotoxin C; 
TSST-1, toxic shock syndrome toxin-l; SPEA, streptococcal pyrogenic exotoxin A). (B) Non-superantigenic bacterial products at 1 
ng/mL (SPEB, streptococcal pyrogenic exotoxin B; LPS, Iipopolysaccharide), IO ng/mL (ProteinA, staphylococcal protein A; ExA, 
Pseudomonas exotoxin A; PepG, peptidoglycan) or 100 ng/mL (LTA, lipoteichoic acid). (C) Cytokines at 10 ng/mL (TNF-(u, human 
tumor necrosis factor alpha; IL-6, human interleukin-6; IL-8, human interleukin-8; MCP-1, human macrophage chemoattractant 
protein 1; PAI-la and PAI-II, human plasminogen activator inhibitor active form and latent form). (D) Antibiotics tested at 10 pg/mL 
(ABK, arbekacin; PCG, penicillin G; MCZ, miconazole), at 20 kg/mL (CLDM, clindamycin; CCL, cephachlor) or at SO kg/mL (VCM, 
vancomycin) (all of the above materials were tested in fetal calf serum). (E) Human plasma proteins (TP, total protein; IgA, IgG and 
IgM, immunoglobulins A, G and M; C3, C4 and C5, complement factors 3, 4, and 5; BZMG, f3z-microglobulin; Tbil, total bilirubin; 
Mgb, myoglobin; Alb, albumin; HDL, high-density lipoprotein; LDL, low-density lipoprotein). 
cytokine production by human peripheral blood cells in 
an in vitro system. In this experiment,TSST-1 was added 
to human plasma at 1000 pg/mL. The plasma was in- 
cubated with or without the SAAD, and the residual 
SAg activity in the plasma was evaluated by determining 
TNF-a and IL-8 production by human blood cells (Figure 
3). 
Incubation of TSST-l-containing plasma with the 
SAAD resulted in a dramatic decrease in the concen- 
tration of TSST-1 to 93.8 pg/mL (Figure 3A). No signi- 
ficant decrease in TSST-1 concentration was noted in 
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incubations without the SAAD. On stimulation with the 
SAAD-treated plasma, human blood cells produced 
TNF-(x and IL-8 to levels of 125 and 359 pg/mL, respec- 
tively (Figure 3B,C). In contrast, stimulation with the 
SAAD-untreated plasma resulted in production of TNF- 
(Y and IL-8 to levels of 194 and 1029 pg/mL, respectively 
(Figure 3B,C).Thus, values for the efficacy of the SAAD 
in removing TSST-1 from human plasma under the 
above conditions were calculated to be 36% and 65% in 
terms of reductions in the induction of TNF-ok and IL-8 
production, respectively, by human blood cells. Statistical 
B 
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Figure 3. Toxic shock syndrome toxin-l (TSST-I) removal efficacy of the superantigen-adsorbing device (SAAD), and the residual 
TSST-1 activity in inducing cytokine production by human blood cells. (A) Residual TSST-1 concentration after incubation of TSST-I- 
containing plasma (I ng/mL) with the SAAD (0.065 g/mL). (8) Tumor necrosis factor alpha (TNF-o) production by human blood cells 
stimulated with SAAD-treated or untreated TSST-l-containing plasma. (C) Interleukin-8 (IL-8) production by human blood cells 
stimulated with WAD-treated or untreated TSST-l-containing plasma. Error bars represent &SD. *Significantly different from the 
control by the Student t-test (P<O.OOl). 
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analysis indicated that these cytokine production- 
inducing activities were significantly lower in the 
SAAD-treated plasma than in SAAD-untreated plasma 
(P<O.OOl). 
Therapeutic blood purification in a superantigen- 
mediated shock model 
To evaluate the SAg-removal efficacy, SAAD was 
examined in a SAg-mediated shock model using an 
experimental extracorporeal blood purification system. 
The SAg-mediated shock hypotension, which may cause 
death, was induced by intravenous administration of 
TSST-1 and LPS into rabbits. 
When a SAAD-containing column was used in the 
extracorporeal circulation system, 50% of the animals 
survived for 14 days after the shock induction by LPS. 
In contrast, no survivals were observed even 3 days after 
the LPS challenge when the extracorporeal blood 
purification was performed using a blank column in 
place of the SAAD column (Figure 4A). No deaths were 
noted when animals were treated with either TSST-1 
alone or LPS alone during the subsequent 14-day 
period (data not shown). 
The circulating blood was monitored for TSST-1 
concentration at both the inlet and the outlet of the 
SAAD column at a time point of 60 min after the 
initiation of the TSST-1 infusion, and a statistically 
significant decrease (inlet, 135 pg/mL?41 pg/mL; out- 
let, 124 pg/mL+37 pg/mL; paired t-test, P=O.O3) was 
detected (Figure 4B). TSST-1 concentration in the 
circulating blood decreased with time, and TSST-1 was 
no longer detected even at the inlet of the SAAD 
column at a time point of 120 min after the initiation 
of the TSST-1 infusion (in other words, 60 min after 
the completion of the TSST-1 infusion). When a blank 
column was used in place of the SAAD column, no 
significant changes in TSST-1 concentration were 
observed during the whole monitoring period of 195 min 
after the initiation of the TSST-1 infusion, 
Gross observation of the general condition of the 
animals revealed hypotension, acidosis, leucopoenia and 
hypoxemia in all animals after the challenge with LPS, 
regardless of whether the extracorporeal circulation was 
passed through a SAAD column or a blank column. 
Thus, no significant differences were detected in the 
incidence of these symptoms between the two groups 
(data not shown). 
DISCUSSION 
In the present study, a new SAAD has been developed 
as a material with potential use in an extracorporeal 
circulation system for treatment of septic patients. 
The basic design of the SAg adsorbent was based 
on our previous findings that a polystyrene-based com- 
posite fiber exhibited high biocompatibility and low 
bloodflow resistance.li For selective trapping of a given 
SAg, an antibody to the given SAg or MHC class II 
molecule with high selectivity for certain SAgs would be 
a most promising ligand. However, these protein mole- 
cules are generally unstable under the conditions usually 
employed in autoclave or gamma ray sterilization pro- 
cedures. Thus, these molecules were discounted, and 
a random screening was carried out with over 100 
chemical moieties with different structures, using in vitro 
adsorption rates of TSST-1 as the index. 
As a result of the screening, 4-chlorophenylurea 
groups were selected, and were introduced via a poly- 
amine spacer molecule by chemical modification (Figure 
1). 
To examine the adsorption selectivity, the adsorption 
rates were determined by using five different SAgs. In 
this connection, cytokine production is considered to be 
an important event in the pathogenesis of SAg-related 
infectious diseasesi and also some antibiotics are 
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Figure 4. Efficacy of the superantigen-adsorbing device (SAAD) in TSST-l/LPS-infused rabbits. (A) Survival curves for rabbits treated 
with the SAAD column (n=8) or blank column (n=8). The survival rate in the SAAD column-treated group was significantly higher 
than that in the blank column-treated group (by the Kaplan-Meier method and log-rank test, P~0.01). (B) TSST-1 concentrations in 
the circulating blood. In the rabbits treated with the WAD column, the TSST-1 concentration in the circulating blood was significantly 
lower at the outlet than at the inlet at a time point of 60 min after the initiation of TSST-1 infusion (by paired t-test, P=O.O3). 
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routinely used in the treatment of patients with bacterial 
infections. Thus, the abilities of the SAAD to adsorb 
some cytokines and antibiotics were also examined. 
The results revealed that the selectivity of the 
adsorption by the SAAD was rather broad (Figure 2). 
Since the five SAgs exhibit no apparent homology in 
their amino acid sequences, and the SAAD also 
exhibited high affinities for a wide variety of structurally 
unrelated non-superantigenic molecules, it is unlikely 
that the amino acid sequence of SAgs is a major factor 
in determining their affinities. Thus, we speculate that 
the urea bond of the 4-chlorophenylurea groups plays a 
critical role in trapping these molecules by interacting 
with them, probably through hydrogen bonding, 
although the detailed adsorption mechanism currently 
remains to be clarified. 
With respect to the affinities of the SAAD toward 
SAgs, the adsorption rates of over 70% in 2-h incuba- 
tions were relatively high, compared with those reported 
with other polymer adsorbents.12 Furthermore, the 
observation that the SAAD is resistant to sterilization 
and is stable for at least 6 months suggests that the 
SAAD is suitable for practical use for medical devices. 
SAg-removal efficacy was evaluated biologically, 
using the cytokine induction assay. Since, as shown 
above, the SAAD exhibited some ability to adsorb 
cytokines, the SAAD was removed before the incuba- 
tion with blood cells, and the supernatant was examined 
for the residual activity of TSST-1. Although there were 
some apparent discrepancies between the removal rate 
of TSST-1 and the rates of reductions in TNF-a and IL- 
8 production (Figure 3) the results at least indicated that 
the SAAD would be effective in reducing the systemic 
inflammation by trapping circulating SAgs. 
The possible application of the SAAD as a blood 
purification device to treat SAg-associated disorders 
was examined in an animal model developed in rabbits 
by treating them with infusions of TSST-1 and LPS. An 
improvement in survival rate and a decrease in TSST-1 
concentration between the blood samples from the inlet 
and outlet of the column were observed. 
These in vitro and in vivo results could be inter- 
preted to mean that the removal of TSST-1 by the 
SAAD results in a reduction in cytokine production and 
suppression of TSST-l-LPS synergism. Also, this SAg 
adsorption must be one of the main reasons for the 
reduction in the severity of septic symptoms. On the 
other hand, it is also possible that the increased survival 
rate was due to the removal of LPS or cytokines, rather 
than TSST-1, since the SAAD exhibited a moderate 
affinity towards LPS and inflammatory cytokines (Figure 
2B). 
Unfortunately, because of the sample limitation, we 
were unable to determine the concentrations of LPS 
or cytokines in the present study. To distinguish the 
contribution of the removal of TSST-1 from other 
factors, animal models of SAg-induced shock developed 
without the concomitant use of LPS, or an infection 
model of SAg-producing Gram-positive bacteria, would 
provide crucial evidence for the role of TSST-1 and its 
removal by the SAAD. In fact, the dose of 0.05 kg/kg 
per hour used in our model was selected to obtain blood 
concentrations around the mean TSST-1 concentration 
(440 pg/mL) reported to be seen in the circulation of 
TSS patients;4 however,TSST-1 at this infusion dose was 
found to cause no lethal toxicity in rabbits. Accordingly, 
it was decided to use LPS in combination with TSST-1 
in this model to induce lethal toxicity, considering the 
synergistic effect of SAgs and LPS.2”,21 
Despite the remarkable increase in survival, no 
significant differences were observed in the incidences 
of the septic symptoms, such as hypotension, acidosis, 
leucopoenia, and hypoxemia. These results suggested 
that the removal of the TSST-1 by the SAAD did not 
affect the development of acute shock, but rather the 
development of more serious toxic events, such as organ 
failures, that were linked to death in the later stages of 
sepsis. 
Protection against superantigen toxicity in vivo 
may be achieved by using neutralizing peptides.22,2” 
Continuous use of such antigenic peptides, however, 
may result in immunosuppression and anaphylactic 
shock. Thus, repeated or continuous use of these 
peptides, which are frequently required in the treatment 
of prolonged infectious diseases, is not considered to 
be appropriate in clinical practice. In the case of extra- 
corporeal circulation, the chance of such problems arising 
would be negligible. 
In conclusion, the SAAD with 4-chlorophenylurea 
as the functional group appears to exhibit rather 
selective and high affinity towards various SAgs, and low 
affinities towards most of the major protein components 
of plasma. The markedly improved survival rate 
observed in the SAAD-treated animals strongly 
suggests the usefulness of the SAAD for removing SAgs 
in clinical settings, although further studies are needed 
to fully characterize the adsorption properties. 
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